Skip to main content
. Author manuscript; available in PMC: 2021 Aug 14.
Published in final edited form as: Biochem J. 2020 Aug 14;477(15):2893–2919. doi: 10.1042/BCJ20190839

Figure 3. Chemical structures of several KRAS signaling inhibitors.

Figure 3.

(A) Compound 11 binds to the p1 allosteric pocket on KRAS to inhibit its function; image reused with permission from McCarthy et al. [140] (https://pubs.acs.org/doi/10.1021/acsomega.8b03308). (B) Fendiline inhibits acid sphingomyelinase in the lysosome, resulting in PtdSer and KRAS mislocalization from the PM. (C) G01 inhibits acid sphingomyelinase as well but also perturbs RAS recycling to the PM through the recycling endosome pathway by inhibiting APEH; republished with the permission of ASBMB, from “An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth”, Tan et al., vol. 293, issue 35, 2018; permission conveyed through Copyright Clearance Center, Inc. [271]. (D) C7 selectively inhibits PI4KIIIα leading to depletion of PI4P from the PM and concomitant mislocalizaion of PtdSer and KRAS; image reused from Raubo et al. with permission from Royal Society of Chemistry [340].